Alongside margin recovery, Biocon Biologics has also gained market share, with oncology remaining a key focus area.

The company, which has been pushing its IPO plans for the past year, has been waiting to complete the integration of its acquired biosimilars firm Viatris and refinance debt before it goes public ...

Peter Bains, Group CEO of Biocon, talks about India's budget, and the impact of its plans to cut or remove duties on ...

Tambe said the company, a subsidiary of the Bengaluru-based Biocon Ltd, has five products in the pipeline for launch in the US, including Bevacizumab in oncology, insulin Aspart in diabetes, and ...

Indian biopharmaceutical firm Biocon is likely to list its key biosimilars business by March 2026 and aims for double-digit share in its core U.S. market for its new launches, a top executive told ...

Hyderabad: Biopharma major Biocon plans to introduce five new biosimilars in the United States in the new fiscal year, ...

Biocon in its Environmental, Social and Governance (ESG) scores as assessed by S&P Global’s Corporate Sustainability Assessment (CSA) for 2024 has achieved an improvement to 69 in 2024, up 6 points ...

Our Bureau, Bengaluru Friday, January 31, 2025, 11:30 Hrs [IST] ...

The company plans to launch five new biosimilars in the U.S. in the new fiscal year, starting in April, and is aspiring for double-digit market share for them, Biocon Biologics CEO Shreehas Tambe ...